GA101

DRUG7 trials

Conditions

CD20 Positive Diffuse Large B-cell LymphomaChronic Lymphocytic LeucemiaChronic Lymphocytic LeukemiaDiffuse Large B Cell Lymphoma CD20 PositiveElderly Unfit PatientsLeukemia, Lymphocytic, Chronic, B-Cell

Phase 1

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

CompletedNCT02315768

University of California, San DiegoChronic Lymphocytic Leukemia

Start: 2015-08-26End: 2022-04-18Updated: 2025-09-15

Phase 2

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

CompletedNCT02345863

German CLL Study GroupChronic Lymphocytic Leucemia

Start: 2015-01-16End: 2019-03-29Updated: 2019-05-08

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

CompletedNCT02401503

German CLL Study GroupChronic Lymphocytic Leucemia

Start: 2015-05-06End: 2024-12-17Updated: 2025-06-10

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

CompletedNCT02445131

German CLL Study GroupChronic Lymphocytic Leucemia

Start: 2015-05-28End: 2022-03-09Updated: 2024-05-09

GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma

TerminatedNCT02495454

Fondazione Italiana Linfomi - ETSCD20 Positive Diffuse Large B-cell Lymphoma, Elderly Unfit Patients

Start: 2015-08-25End: 2017-03-22Updated: 2020-11-05

Phase II Trial GA101 Inbrutinib B CLL

CompletedNCT02666898

French Innovative Leukemia OrganisationLeukemia, Lymphocytic, Chronic, B-Cell

Start: 2015-10-31End: 2023-09-30Updated: 2025-11-26

Phase 3

GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma

TerminatedNCT01659099

The Lymphoma Academic Research OrganisationDiffuse Large B Cell Lymphoma CD20 Positive

Start: 2012-09-30End: 2017-12-31Updated: 2018-03-07

Blood Advances2025-03-033 citations

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood2024-11-052 citations

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood2024-04-1525 citations

Validation of the ΔSUV<sub>max</sub>for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial

Journal of Nuclear Medicine2023-09-218 citations

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Blood Advances2023-04-077 citations

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood2022-11-15

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology2022-01-223 citations

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years

Cancers2021-09-078 citations

Durable remissions following combined targeted therapy in patients with CLL harboring <i>TP53</i> deletions and/or mutations

Blood2021-06-0412 citations

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.

2021-02-0114 citations

Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA

Blood2020-11-2072 citations

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood2020-11-0913 citations

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Blood2020-11-04

Molecular Characterisation of Diffuse Large B Cell Lymphoma in Patients of 80 Years Old or More: Clinical Relevance in a Multicentric Randomized Phase III Study of the Lysa (SENIOR Study)

Blood2019-11-131 citations

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Blood2019-11-13

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

2019-07-1618 citations

Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma Cytokine Levels

Blood2018-11-291 citations

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.

2018-08-1382 citations

Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.

Journal of Clinical Oncology2018-05-20

CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.

2018-02-2123 citations

GA101

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers